Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | GRB2 | P62993 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272846 | 0.84 | PTPN1 (0.40) | CYP2A6PTPN1CHRNA7P2RX1P2RX4 | |
| SCHEMBL4312243 | 0.81 | MIF (0.50) | GRB2MIFCYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL23457137 | 0.79 | MIF (0.48) | GRB2MIFCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9315537 | 0.78 | KIF11 (0.44) | SLC22A12PTGDRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16595353 | 0.77 | TSHR (0.48) | CYP1A2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL29374749 | 0.77 | CYP2A6 (0.50) | CYP2A6PTPN1CHRNA7P2RX1P2RX4 | |
| SCHEMBL22401519 | 0.77 | CYP2A6 (0.50) | CYP2A6PTPN1CHRNA7P2RX1P2RX4 | |
| SCHEMBL16681508 | 0.76 | NPC1 (0.45) | GRB2SLC22A12RAB9ATSHRSMN1; SMN2 | |
| Bicarbonate SCHEMBL29074426 | 0.76 | CYP2A6 (0.59) | CYP2A6F7F3CYP1A2RAB9A | |
| SCHEMBL1774639 | 0.76 | TSHR (0.48) | GRB2SLC22A12RAB9ATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP2A6 1882/4885PTPN1 4119/4885CHRNA7 3335/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP2A6 1882/4885PTPN1 4119/4885CHRNA7 3335/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP2A6 1882/4885PTPN1 4119/4885CHRNA7 3335/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP2A6 1882/4885PTPN1 4119/4885CHRNA7 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.